N/A N=2,384 Modeling Clinical Failure in Prostate Cancer Patients Based on a Two-stage Statistical Model
Prostate Cancer
Primary: Number of Participants With Clinical Failure After Initiation of Radiotherapy — 315 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=431 Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors (PROGRESS)
Prostate Cancer
Primary: Adaptive Coping — -0.089; -0.013 score on a scale — p=.9634
Phase 3 N=478 Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
Prostate Cancer
Primary: Time to Progression — 683.0; 549.0 days — p=0.76
N/A N=450 Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)
Cancer
Primary: Proportion of Patients Being Receiving Treatment Administration After Diagnosis — 372 Participants
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
N/A N=37 Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2
Critical Illness · Oncology · Communication
Primary: Change in Prognostic Understanding — 0.58; 0.18 units on a scale
Phase 2 N=69 Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
N/A N=4,322 Care Coordination for Complex Cancer Survivors in an Integrated Safety Net System
Breast Cancer · Colorectal Cancer
Primary: Proportion of Complex Cancer Survivors Meeting Quality of Care Guidelines for Chronic Conditions and Follow-up Cancer Surveillance
N/A N=23 App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer
Cancer
Primary: Interviews — 20 Interviews
N/A N=204 The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy
Non-small Cell Lung Cancer
Primary: To Describe the Pattern of CTCs Before and After Definitive Radiotherapy for Each Treatment Stratum — 3.9; 9.1; 9.1; 9.1 CTCs/mL
N/A N=15 Cancer Anorexia and the Central Nervous System
Cancer Cachexia
Primary: ACTIVATION/NON ACTIVATION OF SPECIFIC BRAIN AREAS, EVALUATED BY FUNCTIONAL MAGNETIC RESONANCE — 585.57; 667.92; 511.22 BOLD
Phase 4 N=90 Tobacco Use Treatment in Cancer Patients
Smoking, Cigarette
Primary: Smoking 7-Day Point Prevalence at 12 Weeks — 2; 2; 3 Participants
Phase 2 N=113 Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
Metastatic Androgen Independent Prostate Cancer
Primary: Safety of APC8015F by Review of Reported Adverse Events — 109 Participants
N/A N=35,953 Cancer Prevention Clinical Decision Support
Cancer Prevention
Primary: Composite Cancer Screening Tests up to Date — 3087; 2590; 3866 Participants — p=.025
Phase 1 N=84 A Study in Advanced Cancer
Advanced Cancer
Primary: Recommended Phase 2 Dose: Maximum Tolerated Dose — 400 milligrams (mg)
Phase 2 N=105 Taxol Carboplatin and Erythropoetin
Ovarian Cancer
Primary: Progression-free Survival. Progression is Defined According WHO-criteria as Appearance of Any New Lesion or Increase of Existing Lesions by at Least 25% — 28.8 months
Phase 2 N=154 PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Stage I Prostate Adenocarcinoma AJCC v7 · Stage II Prostate Adenocarcinoma AJCC v7
Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2
N/A N=66 Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy
Patients With High-risk Prostate Cancer
Primary: Number of Participants With Circulating Tumor Cells in the Peripheral Blood — 60; 5 Participants
N/A N=469 Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer
Sarcopenia · Non Small Cell Lung Cancer · Malnutrition
Primary: Progression Free Survival (PFS) — 350; 773 days
Phase 2 N=28 Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
Urinary Bladder Neoplasms
Primary: Number of Participants With Freedom From Progression of Cancer at 4 Months — 20 Participants
N/A N=303 Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial
Smoking Cessation
Primary: Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months — 29; 51 Participants
N/A N=562 Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer
Cancer
Primary: Number of Study Participants Who Have Completed a Palliative Care Visit Within 3 Months of Enrollment — 22; 130 participants
N/A N=20 Giving Information Systematically and Transparently in Lung and GI Cancer Phase 1
Critical Illness · Oncology · Communication
Primary: Acceptability of the Proposed Intervention According to a Structured Qualitative Survey of Caregivers — 9; 10; 1; 3 Participants
Phase 2 N=75 Priming Immunotherapy in Advanced Disease With Radiation
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=647 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
N/A N=1 LiveWell: Adapted DBT Skills Training for Metastatic Lung Cancer
Cancer Metastatic to Lung
Primary: Usability as Measured by the Total Number of Participants Who Complete the Study Questionnaires — 1 Participants
Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
N/A N=2,074 Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions
Neoplasm
Primary: Proportion of Patients With a Reportable Genetic Variant — 0.61 proportion of participants